Related Experiment Videos
[Neuromodulators and Alzheimer's disease]
1Institutions Universitaires Psychiatriques de Genève, Division de Psychopathologie morphologique, Chêne-Bourg, Suisse.
L'Encephale
|September 1, 1988
Summary
Alzheimer's disease (AD) involves brain changes like plaques and tangles, leading to dementia. Neurochemical deficiencies, particularly in the cholinergic system, are key features of AD pathology.
Area of Science:
- Neuroscience
- Neuropathology
- Neurochemistry
Context:
- Alzheimer's disease (AD) is a leading cause of dementia, affecting over 50% of elderly dementia cases.
- AD is clinically defined by memory loss and cognitive impairments (aphasia, apraxia, agnosia).
- Pathological hallmarks include neuritic plaques, neurofibrillary tangles, and neuronal loss in the neocortex and hippocampus.
Purpose:
- To review existing literature and present new findings on neurochemical alterations in Alzheimer's disease.
- To investigate neurotransmitter systems affected in AD, beyond the well-documented cholinergic deficit.
Summary:
- Alzheimer's disease is characterized by specific neuropathological changes and significant neurochemical deficiencies.
- The cholinergic system is notably vulnerable in AD.
- Other significantly affected neurotransmitter systems include somatostatin, substance P, neuropeptide Y, corticotropin-releasing factor, and glutamate.
Impact:
- Highlights the complex neurochemical landscape of Alzheimer's disease.
- Provides a foundation for understanding AD's molecular mechanisms.
- Informs potential therapeutic strategies targeting specific neurotransmitter systems.